AASLD News

AASLD is pleased to announce the selection of thirty hepatology leaders as Fellows and two allied health leaders focused on hepatology as Associate Fellows. The Fellows Programs bestows honorary recognition upon AASLD members who have made a significant contribution to the knowledge and/or practice of liver and biliary diseases, and are considered leaders in the field. Associate Fellow of the

ALEXANDRIA, VA – The American Association for the Study of Liver Diseases (AASLD) applauds the White House for including a bold five-year plan to eliminate hepatitis C in the Fiscal Year 2024 budget request. We are pleased to support this plan which calls for the acceleration of the availability of point-of-care diagnostic tests, the expansion of access to curative therapies, and the

The American Association for the Study of Liver Diseases (AASLD) is deeply saddened to hear about the Kahramanmaras earthquake that has caused thousands of injuries and deaths, and widespread devastation in Turkey and Syria. Our thoughts and prayers go out to those impacted by this terrible tragedy. The AASLD – TASL CONNECT event was set to take place on February 10-11, 2023 in Ankara, Turkey, and

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) is pleased to announce that Dr. Joseph K. Lim, MD, FAASLD of Yale University will serve as the next Editor-in-Chief of Clinical Liver Disease (CLD), a free multimedia review journal that aims to provide education for clinicians diagnosing and managing patients with liver disease. Dr. Lim is a Professor of Medicine

AASLD Hepatology Award with Harold Amos Medical Faculty Development Program Applications Open February 8 In support of our unwavering commitment to champion diversity, equity, and inclusion in the field of hepatology, AASLD is pleased to announce the development of our own hepatology award. We have partnered with the Robert Wood Johnson Foundation’s Harold Amos Medical Faculty Development Program

Alexandria, VA – Join the greatest minds in hepatology across the continent for a game-changing two-day event, the 2023 North American Viral Hepatitis Elimination Summit, on March 24-25 in Los Angeles. With the goal of achieving viral hepatitis elimination and reducing liver complications including liver cancer among North Americans, the American Association for the Study of Liver Diseases (AASLD)

My esteemed colleagues, It’s truly an honor to represent all of you as president of our society this year. Much has changed over the last few years, but one thing that’s remained the same is our deep commitment to improving the lives of millions of people around the world who suffer from liver disease. At AASLD our number one goal is to provide all of you with the tools, resources, and knowledge

Severe alcohol-associated liver disease (ALD) cases and deaths are the rise,1 creating a pressing need for hepatologists to deliver high quality, high impact care to patients with unhealthy alcohol use. Most patients with ALD also have alcohol use disorder (AUD), and effective ALD care requires treating both disorders.2 Beyond giving advice to abstain, however, many hepatologists lack the training

Alexandria, VA – Registration is now open for the American Association for the Study of Liver Diseases’ (AASLD) 2022 Industry Colloquium: Perspectives and Advances in Liver Preservation on November 3 in Washington, DC. New advances around perfusion devices are changing the game by keeping transplant livers alive longer, allowing for transportation of longer distances. New technology also enhances

The 2-day meeting in Chicago on 8-9 July 2022 convened 129 consensus survey participants in person or online. The participants originated from 32 countries, representing multiple societies including AASLD, EASL, APASL, ALEH, AGA and UEG, patients and patient advocacy organizations, regulators and industry representatives. View the NAFLD Nomenclature Consensus Meeting High-Level Output in Spanish

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, today announced its combined investment of over $1.5 million in Research and Career Development Awards, Abstract Awards, Emerging Liver Scholars (ELS) Program for medical residents and its new Emerging Liver

July 14, 2022 Update The New England Journal of Medicine has recently published two new research articles on this issue, along with an editorial from AASLD Board Councilor and Future President, Saul Karpen, MD, Ph.D., FAASLD. Read the latest here: A Case Series of Children with Acute Hepatitis and Human Adenovirus Infection Clinical Spectrum of Children with Acute Hepatitis of Unknown Cause Read

It is difficult to know whether liver transplant recipients are at higher risk of severe disease, hospitalization, and death from COVID-19 compared to the general population. Case series and registry studies suggest that liver transplantation and immunosuppression do not lead to worse COVID-19 outcomes. However, the CDC has identified organ transplantation and immunosuppression as conditions that

The Centers for Disease Control and Prevention (CDC) has reported a cluster of children identified with acute hepatitis and adenovirus infection in Alabama, and similar reports have surfaced in the UK. Several have undergone liver transplantation, and none have died. All the children were previously healthy and an association between adenovirus and pediatric hepatitis is currently being